ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium

    Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience

    Angela Chun1, MaiLan Nguyen1, Marietta De Guzman2 and Andrea Ramirez3, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…
  • Abstract Number: 183 • 2020 Pediatric Rheumatology Symposium

    Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship

    Alaina Linafelter1, Julia Harris 2, Rob Herr 1, Stephanie Quinn 1 and Ashley Cooper 3, 1Children's Mercy Kansas City, Kansas City, Missouri, 2Children's Mercy Kansas City, Overland Park, 3Children's Mercy Kansas City, Kansas City

    Background/Purpose: Biologic medications are commonly utilized to treat pediatric rheumatic diseases.  Being high-cost, most third-party payors require dispensing through a specialty pharmacy.  Common challenges with…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: L12 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

    Evgeniy Nasonov 1, Saeed Fatenejad 2, Elena Korneva 3, Diana Krechikova 4, Alexey Maslyansky 5, Tatyana Plaksina 6, Marina Stanislav 7, Rumen Stoilov 8, Tamara Tyabut 9, Sergey Yakushin 10, Elena Zonova 11 and Mark Genovese12, 1FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, 2SFC Medica, Charlotte, North Carolina, 3R-Pharm, Moscow, Russia, 4Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, 5SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, 6SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, 7V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 8UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, 9Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, 10Ryazan State Medical University, Ryazan, Russia, 11Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, 12Stanford University, Stanford, CA

    Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: 937 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

    Désirée van der Heijde1, Lianne Gensler 2, Atul Deodhar 3, Xenofon Baraliakos 4, Denis Poddubnyy 5, Alan Kivitz 6, Marga Oortgiesen 7, Dominique Baeten 8, Nadine Goldammer 9, Jason Coarse 7, MK Farmer 7 and Maxime Dougados 10, 1Leiden University Medical Center, Leiden, Netherlands, 2University San Francisco California, San Francisco, CA, 3Oregon Health & Science University, Portland, OR, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 6Altoona Center for Clinical Research, Duncansville, PA, 7UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 8UCB Pharma, Brussels, Belgium, Brussels, 9UCB Pharma, Monheim, Germany, Monheim, Germany, 10Cochin Hospital, Paris, France

    Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
  • Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting

    Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

    Takeshi Shoda1, Tohru Takeuchi 2, Takuya Kotani 2, Koji Nagai 2, Kennichiro Hata 2, Shigeki Makino 2 and Shigeki Arawaka 2, 1Yodogawa christian hospital / Osaka medical college, Osaka, Japan, 2Osaka medical college, Osaka, Japan

    Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
  • Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting

    High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis

    Jun Inamo1, Yuko Kaneko 2, Jun Kikuchi 3 and Tsutomu Takeuchi 4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 4Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
  • Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting

    Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors

    Karina Bonfiglioli1, Márcio Sawamura 2, Renato Nakagawa 3, Fábio Arimura 3, Diana Rangel 3, Cleonice Bueno 4, Ana Cristina de Medeiros Ribeiro 1, Carlos Carvalho 3, Eloisa Bonfa 5, Ronaldo Kairalla 3 and Leticia Kawano-Dourado 6, 1Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, 3Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, 6University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
  • Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting

    Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

    Paul Bird1, Geoffrey Littlejohn 2, Belinda Butcher 3, Tegan Smith 4, Candida da Fonseca Pereira 5, David Witcombe 5 and Hedley Griffiths 6, 1Optimus Research, Kogarah, New South Wales, Australia, 2Monash Rheumatology, Clayton, Victoria, Australia, 3WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, 4OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, 5Pfizer Australia, Sydney, New South Wales, Australia, 6Barwon Rheumatology Service, Geelong, Victoria, Australia

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
  • Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting

    Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

    Raphaèle Seror1, Alexandre Lafourcade 2, yann De Rycke 2, Bruno Fautrel 3, Xavier Mariette 4 and Florence Tubach 5, 1Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 2Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 3Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France

    Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
  • Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting

    Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
  • Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting

    Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry

    Joel Kremer1, Clifton Bingham 2, Laura Cappelli 2, Jeffrey Greenberg 3, Jamie Geier 4, Ann Madsen 4, Connie Chen 4, Alina Onofrei 5, Christine Barr 5, Dimitrios Pappas 6, Heather Litman 5, Kimberly Dandreo 5, Andrea Shapiro 7, Carol Connell 8 and Arthur Kavanaugh 9, 1Albany Medical College, Albany, NY, 2Johns Hopkins University, Baltimore, MD, 3Corrona, LLC; NYU School of Medicine, Waltham, MA, 4Pfizer Inc, New York, NY, 5Corrona, LLC, Waltham, MA, 6Columbia University, New York, NY, 7Pfizer Inc, Peapack, NJ, 8Pfizer Inc, Groton, CT, 9University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
  • Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting

    A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions

    Tien Nguyen1, Melvin Churchill 2, Robert Levin 3, Guillermo Valenzuela 4, Joseph Merola 5, Alexis Ogdie 6, Ana-Maria Orbai 7, Jose Scher 8, Arthur Kavanaugh 9, Shital Agawane 10, Farid Kianifard 11, Chauncy Rollins 11 and Olivier Chambenoit 11, 1Department of Dermatology, University of California, Irvine, Irvine, CA, 2Arthritis Center of Nebraska, Lincoln, NE, 3Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, 4Integral Rheumatology & Immunology Specialists, Plantation, FL, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 9University of California, San Diego School of Medicine, La Jolla, CA, 10Novartis Healthcare Pvt Ltd, Hyderabad, India, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
  • Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting

    Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
  • 1
  • 2
  • 3
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology